Audrey Simonaggio

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).

Journal: Oncoimmunology

Published: May 15, 2023

Future treatment options in metastatic clear cell renal cell carcinoma.

Future treatment options in metastatic clear cell renal cell carcinoma.

Journal: Bulletin du cancer

Published: June 27, 2022

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.

Journal: International journal of molecular sciences

Published: May 24, 2022

Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review.

Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review.

Journal: Future oncology (London, England)

Published: January 19, 2021

Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments.

Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments.

Journal: Cancers

Published: December 31, 2020

Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 29, 2020

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).

Journal: Cancers

Published: November 07, 2020

Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma.

Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma.

Journal: World journal of urology

Published: July 20, 2020

Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit.

Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit.

Journal: Annals of intensive care

Published: July 07, 2020

BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.

BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.

Journal: Bulletin du cancer

Published: July 05, 2020

Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer

Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer

Journal: Bulletin du cancer

Published: July 05, 2020

Resistance to cancer immunotherapy in metastatic renal cell carcinoma.

Resistance to cancer immunotherapy in metastatic renal cell carcinoma.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: March 10, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026